Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus

Cancer

Volumn 113, Issue 6, 2008, Pages 1302-1308

  Javeri, Heta ^a   Arora, Rohan ^a   Correa, Arlene M ^a   Hofstetter, Wayne L ^a   Lee, Jeffrey H ^a   Liao, Zhongxing ^a   McAleer, Mary F ^a   Maru, Dipen ^a   Bhutani, Manoop S ^a   Swisher, Stephen G ^a   Izzo, Julie G ^a   Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Induction chemotherapy; Localized esophageal cancer; Patient outcome; Survival

Indexed keywords

CISPLATIN; FLUOROURACIL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CORRELATION ANALYSIS; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PREOPERATIVE CARE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 47049108166     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23688     Document Type: Article

References (25)

1. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-467.
2. Tepper JE, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-1092.
3. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19: 305-313.
4. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
5. Suntharalingam M, Moughan J, Coia LR, et al. The national practice for patients receiving radiation therapy for carcinoma of the esophagus: results of the 1996-1999 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2003;56:981-987.
6. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281:1623-1627.
7. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. 1994;86:1086-1091.
8. Ajani J, Bekaii-Saab T. D'Amico TA, et al. Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw. 2006;4:328-347.
9. Rohatgi P, Swisher SG, Correa AM, et al. Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. Cancer. 2005; 104:2365-2372.
10. Kelsey CR, Chino JP, Willett CG, et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys. 2007; 69:770-776.
11. Ajani JA, Komaki R, Putnam JB, et al. A 3-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001;92:279-286.
12. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006;24:259-267.
13. Izzo JG, Malhotra U, Wu TT, et al. Association of activated transcription factor nuclear factor kappaB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol. 2006;24:748-754.
14. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457-1459.
15. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
16. Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007;31:58-64.
17. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199-211.
18. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-146.
19. Malaisrie SC, Hofstetter WL, Correa AM, et al. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2006;107:967-974.
20. Rohatgi PR, Swisher SG, Correa AM, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005;104:1349-1355.
21. Izzo JG, Correa AM, Wu TT, et al. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther. 2006;5:2844-2850.
22. Sims-Mourtada J, Izzo JG, Apisarnthanarax S, et al. Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. Clin Cancer Res. 2006;12:6565-6572.
23. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 2007;26:5674-5679.
24. Luthra MG, Ajani JA, Izzo J, et al. Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res. 2007;13:912-919.
25. Wu X, Gu J, Wu TT, et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol. 2006;24: 3789-3798.